ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
Systemic inflammatory response syndrome | 24.06.03.008; 10.02.01.008; 08.01.05.005 | 0.000241% | | Not Available |
Injection site discolouration | 12.07.03.038; 23.03.03.046; 08.02.03.038 | 0.000821% | | Not Available |
Conjunctival hyperaemia | 06.04.01.004 | 0.000362% | | Not Available |
Musculoskeletal discomfort | 15.03.04.001 | - | - | Not Available |
Inappropriate antidiuretic hormone secretion | 14.05.07.001; 05.03.03.001 | 0.000531% | | Not Available |
Skin swelling | 23.03.03.039 | 0.000241% | | Not Available |
Injection site swelling | 12.07.03.018; 08.02.03.017 | 0.001183% | | Not Available |
Infusion site pain | 12.07.05.002; 08.02.05.014 | 0.000531% | | Not Available |
Type IV hypersensitivity reaction | 10.01.03.022 | 0.000241% | | Not Available |
Injection site discomfort | 08.02.03.018; 12.07.03.019 | - | - | Not Available |
Haemorrhagic transformation stroke | 24.07.04.018; 17.08.01.036 | 0.000241% | | Not Available |
Haemorrhage | 24.07.01.002 | 0.001569% | | Not Available |
Fluid intake reduced | 14.05.10.001 | - | - | Not Available |
Gaze palsy | 17.02.05.044; 06.05.02.014 | 0.000241% | | Not Available |
Temperature intolerance | 08.01.09.022 | 0.003983% | | Not Available |
Hypoaesthesia oral | 07.05.05.003; 17.02.06.021 | 0.000362% | | Not Available |
Breast cancer female | 21.05.01.011; 16.10.01.004 | - | - | Not Available |
Bipolar disorder | 19.16.01.003 | - | - | Not Available |
Cognitive disorder | 19.21.02.001; 17.03.03.003 | - | - | |
Injection site nodule | 23.07.04.009; 12.07.03.034; 08.02.03.034 | - | - | Not Available |
Metabolic disorder | 14.11.01.001 | 0.000241% | | Not Available |
Pulseless electrical activity | 02.03.04.020 | 0.000241% | | Not Available |
Lung neoplasm malignant | 22.08.01.001; 16.19.02.001 | - | - | Not Available |
Cerebrovascular insufficiency | 17.08.02.003; 24.04.06.004 | - | - | Not Available |
Injection site scar | 23.03.11.016; 12.07.03.050; 08.02.03.050 | - | - | Not Available |
Metastases to central nervous system | 17.02.10.013; 16.22.02.004 | - | - | Not Available |
Infusion site rash | 23.03.13.018; 12.07.05.017; 08.02.05.017 | 0.000241% | | Not Available |
Neurological symptom | 17.02.05.010 | 0.000362% | | Not Available |
Adverse event | 08.06.01.010 | - | - | Not Available |
Appetite disorder | 19.09.01.002; 14.03.01.004 | 0.000241% | | Not Available |